4.Aggen D H,Shah N J.,Zheng J T,et al.HER2 and PD-L1 immunohistochemistry(IHC)expression,and HER2 genomic alterations:Associations and clinical outcomes for advanced bladder cancer.2024 ASCO-GU Abstract 538. 5.Zhou L,...
[23]Hirsch, Fred R., et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. Journal of Thoracic Oncology 12.2 (2017): 208-222. [24]Tsao, Ming Sound, ...
无需PD-L1 IHC组织评估:无论PD-L1表达如何,肿瘤类型已被批准使用PD-1/PD-L1免疫疗法进行治疗。 PD-L1免疫组织化学 PD-L1的组织表达已在多种肿瘤类型中进行评估,以预测对这些克隆免疫疗法的疗效。然而,“阳性”PD-L1表达的标准化或可重复性标准从未得到很好的确立,在PD-L1 IHC分析和肿瘤类型之间仍存在争议和变...
免疫组织化学（immunohistochemistry，IHC，简称“免疫组化”）检测是评估肿瘤组织PD-L1表达状态的一种有效且常用的方法，广泛应用于多种恶性肿瘤中，以识别或辅助预测可能从免疫治疗中获益的患者。基于免疫组化法的PD-L1检测试剂操作程序和结果判读较为复杂，该类检测试剂临床应用的准确性与重复性是产品重要的临床性能，...
PD-L1 was interpreted as positive with the SP142 assay in an average 58% of cases compared with 78% with SP263 (p< 0.0001). IC positive continuous scores ranged from 1 to 95% (mean = 20%) and 1 to 90% (mean = 10%) for SP263 and SP142, respectively. With SP142, 26 cases ...
免疫组织化学(immunohistochemistry,IHC,简称免疫组化)检测是评估肿瘤组织PD-L1表达状态的一种有效且最常用方法,广泛应用于包括非小细胞肺癌(non-small cell lung cancer, NSCLC)等在内的多种恶性肿瘤中,以识别或辅助预测可能从免疫治疗中获益的患者。 为更好地指导临床检测,中国抗癌协会肿瘤病理专业委员会肺癌学组...
还利用免疫组化(Immunohistochemistry,IHC)技术检测 PD-L1 和 p53 的表达,以及用苏木精 - 伊红(Hematoxylin-Eosin,H&E)染色评估组织形态。最后,运用多种统计分析方法,如倾向得分匹配(Propensity Score Matching,PSM)、Spearman 检验、Cox 比例风险模型等对数据进行处理。
.003[5]Rimm DL, Han G, Taube JM, et al. A prospective,multi‑institutional, pathologist‑based assessment of 4 immunohistochemistry assays for PD‑L1 expression in non‑small cell lung cancer[J]. JAMA Oncol, 2017, 3(8):1051‑1058. DOI: 10.1001/jamaoncol.2017.0013.[6]Xue, Liyan...
2. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.JAMA Oncol. 2017 Aug 1;3(8):1051-1058 3.Wang Y, Da JP, Wang DW, et al. Quanti...
[6]Tsao, MING SOUND, et al. IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer. Aurora, CO: International Association for the Study of Lung Cancer (2017). [7]Prince, Spasenija Savic, and Lukas Bu...